Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3930572 | European Urology Supplements | 2007 | 6 Pages |
Abstract
Zoledronic acid significantly delays the onset and reduces the incidence of SREs in patients with bone metastases secondary to HRPC and RCC.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Fred Saad,